OrbusNeich Files Suit in Ireland Against Boston Scientific Claiming Patent Infringement

OrbusNeich Medical Inc. and its subsidiary, Orbus International B.V., (collectively, "OrbusNeich") today announced that they have commenced a patent infringement lawsuit in Ireland against Boston Scientific Corporation

and two of its Irish subsidiaries (collectively, "Boston Scientific"). The lawsuit alleges that Boston Scientific are infringing two European patents covering certain novel stent designs.  The two patents, held by OrbusNeich, are designated EP 2 311 412 and EP 1 341 482.  OrbusNeich allege that the patents are infringed by a number of Boston Scientific's coronary stent systems, including the "PROMUS Element™", "PROMUS Element Plus™", "OMEGA™", "TAXUS™", "SYNERGY™", and "Promus PREMIER™" lines of stents. OrbusNeich are seeking damages for the infringement and an injunction prohibiting Boston Scientific from manufacturing, offering for sale, marketing or stocking products that infringe the patents in Ireland. Al Novak, Chairman and Chief Executive Officer of OrbusNeich, said, "The lawsuit in Ireland is a continuation of our efforts to protect and enforce our intellectual property rights. We intend to vigorously pursue these efforts to prevent unlawful competitive practices and protect our unique technologies throughout the world." On February 20, 2013, OrbusNeich commenced patent infringement actions in Germany and the Netherlands against